Safety of pharmacotherapy options for bulimia nervosa and binge eating disorder
Open accessThe DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
Abstract
INTRODUCTION: Eating disorders represent a set of psychiatric illnesses with lifelong complications and high relapse rates. Individuals with eating disorders are often stigmatized and clinicians have a limited set of treatments options. Pharmacotherapy has the potential to improve long term compliance and patient commitment to treatment for eating disorders. AREAS COVERED: This review will examine the efficacy and safety profile of the FDA-approved medications for the treatment of bulimia nervosa (BN) and binge eating disorder (BED). This will include the evaluation of fluoxetine for BN, and lisdexamfetamine for BED. Safety information will be review from randomized control trials (RCT), open label trials, and case reports. EXPERT OPINION: Fluoxetine for BN and lisdexamfetamine for BED are relatively safe and well-tolerated. Despite these properties, these two medications represent a limited arsenal for the pharmacological treatment of eating disorders. Thus, more research-based strategies are needed to develop safe, effective, and more targeted therapies for eating disorders.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The prevalence and correlates of eating disorders in the National Comorbidity Survey Replication
Hudson, J. I., Hiripi, E., Pope, H. G., & Kessler, R. C. (2007) · Biological Psychiatry · doi:10.1016/j.biopsych.2006.03.040 · Cited by 4,973
Cognitive Behavioral Therapy for Eating Disorders
Murphy, R., Straebler, S., Cooper, Z., & Fairburn, C. G. (2010) · Psychiatric Clinics of North America · doi:10.1016/j.psc.2010.04.004 · Cited by 435
(1992) · Archives of General Psychiatry · doi:10.1001/archpsyc.1992.01820020059008 · Cited by 371
McElroy, S. L., Hudson, J. I., Mitchell, J. E., Wilfley, D., Ferreira-Cornwell, M. C., Gao, J., Wang, J., Whitaker, T., Jonas, J., & Gasior, M. (2015) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2014.2162 · Cited by 322 · cited 5×
“5 mean binge eating/ week from baseline) dose of lisdexamfetamine was not different from placebo [33].”
BackgroundMethodInfluentialMcElroy, S. L., Hudson, J., Ferreira-Cornwell, M. C., Radewonuk, J., Whitaker, T., & Gasior, M. (2016) · Neuropsychopharmacology · doi:10.1038/npp.2015.275 · Cited by 254 · cited 4×
“83 mm Hg for diastolic pressure in subjects receiving lisdexamfetamine [32].”
BackgroundMethodInfluentialMicali, N., Martini, M. G., Thomas, J. J., Eddy, K. T., Kothari, R., Russell, E., Bulik, C. M., & Treasure, J. (2017) · BMC Medicine · doi:10.1186/s12916-016-0766-4 · Cited by 245
Aigner, M., Treasure, J., Kaye, W., Kasper, S., & The WFSBP Task Force on Eating Disorders (2011) · The World Journal of Biological Psychiatry · doi:10.3109/15622975.2011.602720 · Cited by 207
Jasinski, D., & Krishnan, S. (2009) · Journal of Psychopharmacology · doi:10.1177/0269881109103113 · Cited by 149 · cited 2×
“For the ARCI, lisdexamfetamine (100 and 150 mg) was significantly higher than placebo for measures of the inventory (p 0.05), but the 50-mg dose was significantly lower than amphetamine (p 0.05) [40].”
MethodInfluentialClinician Reactions to Patients With Eating Disorders: A Review of the Literature
Thompson-Brenner, H., Satir, D. A., Franko, D. L., & Herzog, D. B. (2012) · Psychiatric Services · doi:10.1176/appi.ps.201100050 · Cited by 136
Adler, L. A., Alperin, S., Leon, T., & Faraone, S. V. (2017) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/cap.2016.0121 · Cited by 28
Cited by
Selective Serotonin Reuptake Inhibitors and Adverse Effects: A Narrative Review
Edinoff, A. N., Akuly, H. A., Hanna, T. A., Ochoa, C. O., Patti, S. J., Ghaffar, Y. A., Kaye, A. D., Viswanath, O., Urits, I., Boyer, A. G., et al. (2021) · Neurology International · doi:10.3390/neurolint13030038 · Cited by 440
A review of binge eating disorder and obesity
Agüera, Z., Lozano-Madrid, M., Mallorquí-Bagué, N., Jiménez-Murcia, S., Menchón, J. M., & Fernández-Aranda, F. (2021) · neuropsychiatrie · doi:10.1007/s40211-020-00346-w · Cited by 144
Richards, J., Bang, N., Ratliff, E. L., Paszkowiak, M. A., Khorgami, Z., Khalsa, S. S., & Simmons, W. K. (2023) · Obesity Pillars · doi:10.1016/j.obpill.2023.100080 · Cited by 96
The emerging role of glucagon-like peptide 1 in binge eating
Balantekin, K. N., Kretz, M. J., & Mietlicki-Baase, E. G. (2024) · Journal of Endocrinology · doi:10.1530/joe-23-0405 · Cited by 38
Nourredine, M., Jurek, L., Angerville, B., Longuet, Y., de Ternay, J., Derveaux, A., & Rolland, B. (2021) · CNS Drugs · doi:10.1007/s40263-020-00780-y · Cited by 26
“In the two positive RCTs [60, 62], the reduction in binge frequency observed with topiramate seemed to have approximatively the same effect size as those with selective serotonin reuptake inhibitors [106, 107] or lisdexamfetamine [108].”
Result
Metadata
- Authors
- Bello, N. T., & Yeomans, B. L.
- Venue
- Expert Opinion on Drug Safety
- Publisher
- Informa UK Limited
- Published
- 2017-10-31
- Volume
- 17
- Issue
- 1
- Pages
- 17-23
- ISSN
- 1474-0338 (ISSN-L)
- 1744-764X
- OpenAlex
- W2765566375
- Cited by
- 70
- References
- 11
- FWCI
- 3.48
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Safety of pharmacotherapy options for bulimia nervosa and binge eating disorder. https://app.cochat.ai/papers/10.1080/14740338.2018.1395854
- The paper
- Bello, N. T., & Yeomans, B. L. (2018). Safety of pharmacotherapy options for bulimia nervosa and binge eating disorder. Expert Opinion on Drug Safety. https://doi.org/10.1080/14740338.2018.1395854
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.